Guanfacine XR and ADHD: A Brief Review of Efficacy, Safety, and Clinical Applications in Children and Adolescents

Öz

Guanfacine extended-release (XR) has emerged as an important non-stimulant therapeutic option for the management of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, particularly in cases characterized by inattention, impulsivity, and sleep-related difficulties. Evidence from randomized controlled trials as well as long-term observational studies consistently demonstrates clinically meaningful improvements with guanfacine XR, both when used as monotherapy and in combination with stimulant medications. Through its selective α2A-adrenergic receptor agonism, guanfacine XR modulates prefrontal cortical networks, thereby enhancing executive functioning and supporting behavioral regulation. Although sedation is frequently reported during the early stages of treatment, this effect generally subsides with continued use, and several studies suggest potential benefits for sleep continuity. Importantly, clinical investigations indicate that guanfacine XR provides effective symptom control without impairing cognitive performance, with additional advantages observed in some cases when used adjunctively with stimulants. In Turkey, guanfacine XR is available under the trade names Arislow® and Guago®. Despite international guideline recommendations highlighting its role as a non-stimulant treatment alternative, evidence from local clinical practice remains scarce. Ongoing research is needed to further elucidate its long-term efficacy and safety profile in diverse populations. Additionally, increased awareness and training among healthcare providers in Turkey could enhance its utilization in clinical settings.

Anahtar Kelimeler

• Guanfacine
• ADHD
• pharmacotherapy

Guanfacine XR ve DEHB: Çocuklarda ve Ergenlerde Etkinlik, Güvenlik ve Klinik Uygulamaların Kısa Bir Derlemesi

Öz

Guanfacin uzatılmış salım (XR), çocuk ve ergenlerde dikkat eksikliği ve hiperaktivite bozukluğunun (DEHB) tedavisinde giderek daha fazla önem kazanan stimülan dışı bir farmakoterapi seçeneği olarak öne çıkmaktadır. Randomize kontrollü araştırmalar ve uzun süreli gözlemsel çalışmalar, ilacın hem tek başına kullanımında hem de psikostimülan tedavilere eklenmesi halinde belirgin klinik iyileşmeler sağladığını ortaya koymaktadır. Seçici α2A-adrenerjik reseptör agonizması yoluyla prefrontal korteksteki sinir ağlarını düzenleyerek yürütücü işlevleri ve davranışsal kontrolü desteklediği düşünülmektedir. Tedavinin erken döneminde sedasyon sık gözlenmekle birlikte, genellikle zaman içinde azalma eğilimi gösterir ve bazı olgularda uyku sürekliliği üzerinde ek yararlar bildirilmiştir. Ayrıca, bilişsel performans üzerinde belirgin olumsuz bir etkisinin bulunmadığı ve semptom kontrolünü bozmadığı gösterilmiştir. Türkiye’de Arislow® ve Guago® ticari isimleriyle ruhsatlı olarak bulunan Guanfacin XR, uluslararası kılavuzlarda stimülan dışı tedavi seçenekleri arasında yer almakla birlikte, yerel klinik veriler hâlen sınırlıdır. Çeşitli popülasyonlarda uzun vadeli etkinliği ve güvenlik profilini daha ayrıntılı olarak aydınlatmak için devam eden araştırmalara ihtiyaç vardır. Ayrıca, Türkiye'deki sağlık hizmetleri sağlayıcıları arasında farkındalığın artırılması ve eğitimlerin yaygınlaştırılması, klinik ortamlarda kullanımını artıracaktır.

Anahtar Kelimeler

• Guanfasin
• DEHB
• farmakoterapi

Kaynakça

1. Arnsten, A. F. T. (2009). Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs, 23(Suppl. 1), 33–41. https://doi.org/10.2165/00023210-200923000-00005
2. Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & SPD503 Study Group. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 121(1), e73–e84. https://doi.org/10.1542/peds.2006-3695
3. Cruz, M. P. (2010). Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha(2A)-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. P & T: A Peer-Reviewed Journal for Formulary Management, 35(8), 448–451.
4. Elbe, D. (2014). Review of the pharmacotherapy of irritability of autism and attention-deficit/hyperactivity disorder in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 23(3), 195–202.
5. Faraone, S. V., & Glatt, S. J. (2010). A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. The Journal of Clinical Psychiatry, 71(6), 754–763. https://doi.org/10.4088/JCP.08m04902pur
6. Faraone, S. V., McBurnett, K., Sallee, F. R., Steeber, J., & López, F. A. (2013). Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Clinical Therapeutics, 35(11), 1778–1793. https://doi.org/10.1016/j.clinthera.2013.09.013
7. Huss, M., Chen, W., & Ludolph, A. G. (2018). Guanfacine extended release: A new pharmacological treatment option in Europe. European Child & Adolescent Psychiatry, 27(12), 1571–1581. https://doi.org/10.1007/s00787-018-1186-6
8. Kollins, S. H., López, F. A., Vince, B. D., Turnbow, J. M., Farrand, K., Lyne, A., Wigal, S. B., & Roth, T. (2011). Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 21(3), 245–252. https://doi.org/10.1089/cap.2010.0064

9. Martin, P., Satin, L., & Vince, B. D. (2014). Pharmacokinetics of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Clinical Drug Investigation, 34(12), 875–883. https://doi.org/10.1007/s40261-014-0240-2
10. National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: Diagnosis and management (NICE Guideline NG87). https://www.nice.org.uk/guidance/ng87
11. Newcorn, J. H., Stein, M. A., & Cooper, K. M. (2013). Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended release. Journal of Child and Adolescent Psychopharmacology, 23(6), 434–439. https://doi.org/10.1089/cap.2012.0103
12. Rugino, T. A. (2018). A review of the use of guanfacine ER in children and adolescents with attention-deficit/hyperactivity disorder. Pediatric Drugs, 20(5), 417–428. https://doi.org/10.1007/s40272-018-0302-7
13. Sallee, F. R., & McGough, J. J. (2009). Guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder. Expert Review of Neurotherapeutics, 9(7), 917–925. https://doi.org/10.1586/ern.09.51
14. Sallee, F. R., McGough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009). Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry, 48(2), 155–165. https://doi.org/10.1097/CHI.0b013e318191769e
15. Turkish Medicines and Medical Devices Agency. (2013a). Arislow® prescribing information. Recordati İlaç.
16. Turkish Medicines and Medical Devices Agency. (2013b). Guago® prescribing information. VEM İlaç.
17. U.S. Food and Drug Administration. (2013). Intuniv (guanfacine) extended-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf
18. Wilens, T. E., Bukstein, O., Cutler, A. J., McBurnett, K., Rugino, T., Sallee, F. R., & Youcha, S. (2012). Efficacy and safety of guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 22(6), 402–411. https://doi.org/10.1089/cap.2012.0022
19. Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528
20. Young, J. L., Sarkis, E., Qiao, M., & Wietecha, L. (2014). Once-daily treatment with guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder and oppositional symptoms. Journal of Child and Adolescent Psychopharmacology, 24(8), 424–433. https://doi.org/10.1089/cap.2014.0021
21. Yu, G., Li, G., & Markowitz, J. S. (2023). A systematic review of guanfacine extended release in the treatment of attention-deficit/hyperactivity disorder. Clinical Therapeutics, 45(1), 4–17. https://doi.org/10.1016/j.clinthera.2022.11.006